I think the 20% that is the splinter under your fingernail, is insurance against market fluctuation between now and when the deal is inked, also an incentive to purchase the shares from the company. If not they could go on the open market and get them. That would not help IMGG in any way. As I said before, Dean is looking ahead and this money will finance the company through 2011. We cannot know when the FDA will make a decision.
Market Data 
Markets 
AI
